Sara Abdulrahman Alomar, Sarah Ali Alghabban, HadeelAbdulaziz Alharbi, Mehad Fahad Almoqati, Yazid Alduraibi, Ahmed Abu-Zaid1. Firibastat, the first-in-class brain aminopeptidase a inhibitor, in the management of hypertension: a review of clinical trials
Avicenna Journal of Medecine/Volume 11/Issue 1/January 2021
DOI: 10.4103/ajm.ajm_117_20https://doi.org/10.1016/j.bbadis.2020.166037Canadian Journal of Cardiology 36 (2020) 721e731
doi: https://doi.org/10.1016/j.cjca.2020.03.005
Q. Gao et al. Newt drug targets for hypertension: A literature review. BBA-Molecular Basis of Disease. Volume 1867, Issue 3, 1 March 2021, 166037
https://doi.org/10.1016/j.bbadis.2020.166037Canadian Journal of Cardiology 36 (2020) 721e731
doi: https://doi.org/10.1016/j.cjca.2020.03.005
Azizi M, Courand PY, Denolle T, Delsart P, Zhygalina V, Amar L, Lantelme P, Mounier-Vehier C, De Mota N, Balavoine F, Llorens-Cortes C. A pilot double-blind randomised placebo-controlled crossover pharmacodynamic study of the centrally active aminopeptidase A inhibitor, firibastat, in hypertension.
J Hypertens. 2019 Aug;37(8):1722-1728.
doi: 10.1097/HJH.0000000000002092.
EN SAVOIR PLUSFerdinand KC, Balavoine F, Besse B, Black HR, Desbrandes S, Dittrich HC, Nesbitt SD. Efficacy and Safety of Firibastat, A First-in-Class Brain Aminopeptidase A Inhibitor, in Hypertensive Overweight Patients of Multiple Ethnic Origins.
Circulation. 2019 Jul 9;140(2):138-146. doi: 10.1161/CIRCULATIONAHA.119.040070.
EN SAVOIR PLUSKeck M, De Almeida H, Compère D, Inguimbert N, Flahault A, Balavoine F, Roques B, Llorens-Cortes C. NI956/QGC006, a Potent Orally Active, Brain-Penetrating Aminopeptidase A Inhibitor for Treating Hypertension.
Hypertension. 2019 Jun;73(6):1300-1307.
doi: 10.1161/HYPERTENSIONAHA.118.12499.
EN SAVOIR PLUSKeck M, Hmazzou R, Llorens-Cortes C. Orally Active Aminopeptidase A Inhibitor Prodrugs: Current State and Future Directions.
Curr Hypertens Rep. 2019 May 21;21(7):50.
doi: 10.1007/s11906-019-0957-4.
EN SAVOIR PLUSBoitard SE, Marc Y, Keck M, Mougenot N, Agbulut O, Balavoine F, Llorens-Cortes C. Brain renin-angiotensin system blockade with orally active aminopeptidase A inhibitor prevents cardiac dysfunction after myocardial infarction in mice.
J Mol Cell Cardiol. 2019 Feb;127:215-222.
doi: 10.1016/j.yjmcc.2018.12.008
EN SAVOIR PLUSLeenen FHH., Ahmad M., Marc Y, Llorens-Cortes C. Specific inhibition of brain angiotensin III formation as a new strategy for prevention of heart failure after myocardial infarction.
J Cardiovasc Pharmacol. 2019 Feb;73(2):82-91.
doi: 10.1097/FJC.0000000000000638
EN SAVOIR PLUSScientific Conferences
European Society of Cardiology 2019
Boitard-Joanne S, Marc Y, Keck M, Mougenot N, Agbulut O, Balavoine F, LlorensCortes C. Brain reninangiotensin system blockade with firibastat, an orally active, central acting aminopeptidase A inhibitor prodrug prevents cardiac dysfunction after myocardial infarction in mice.
Abstract P4473
EN SAVOIR PLUSKeck M, De Almeida H, Compere D, Inguimbert N, Flahault A, Balavoine F, Roques BP, Llorens-Cortes C. NI956/QGC006, a potent orally active, brainpenetrating aminopeptidase A inhibitor prodrug for treating hypertension.
Abstract P4481
EN SAVOIR PLUSLlorens-Cortes C, Marc Y, Hmazzou R, Keck M, Flahault A, Roques BP, Balavoine F, Azizi M. Centralacting aminopeptidase A inhibitors for new treatment of hypertension: from discovery to clinical trial.
Abstract P4554
EN SAVOIR PLUSAmerican Heart Association 2018
Ferdinand KC, Balavoine F, Besse B, Black HR, Desbrandes S, Dittrich HC, Nesbitt SD. Efficacy and Safety of a Novel Antihypertensive Pharmacotherapy Approach in a High-Risk Diverse Population
Circulation. 2018;138:e766, December 2018
EN SAVOIR PLUSEuropean Society of Hypertension 2017
Azizi, M.; Courand, P.; Denolle, T.; Zhygalina, V.; Delsart, P.; Amar, L.; Lantelme, P.; Deplanque, D.; Mounier-Vehier, C.; Balavoine, F.; Madonna, O.; Llorens-Cortes, C. A randomized double-blind placebo controlled crossover study to compare QGC001, a brain aminopeptidase A inhibitor, with placebo in patients with grade I/II essential hypertension.
J Hypertens. 35:e36, September 2017.
EN SAVOIR PLUSEuropean Society of Hypertension 2016
Hmazzou, R.; Flahault, A.; Marc, Y.; Llorens-Cortes, C. Mode of action of RB150, an aminopeptidase A inhibitor prodrug as a centrally-acting antihypertensive agent in DOCA-salt hypertensive rats.
J Hypertens. 34:e75, September 2016.
EN SAVOIR PLUSMarc, Y.; Hmazzou, R.; Flahault, A.; Llorens-Cortes, C. Central antihypertensive effects of chronic treatment with RB150/QGC001, an orally active aminopeptidase A inhibitor prodrug in DOCA-salt hypertensive rats.
J Hypertens. 34:e103, September 2016.
EN SAVOIR PLUSEuropean Society of Hypertension 2014
Balavoine, F., Azizi, M., Bergerot, D., De Mota, N., Patouret, R., Roques, B.P., Llorens-Cortes, C. Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of QGC001, a centrally-acting aminopeptidase A inhibitor, in healthy volunteers.
J Hypertens. 32:e82, September 2014.
EN SAVOIR PLUSEuropean Society of Hypertension 2013
Balavoine, F., Kousignian, Bergerot, D., De Mota, N., Chassard, D., Segard, L., Roques, B.P., Llorens-Cortes, C., Azizi, M. Safety, tolerability, pharmacokinetics and pharmacodynamics of QGC001, a centrally-acting aminopeptidase A inhibitor, in healthy volunteers.
J Hypertens. 31:e114, September 2013.
EN SAVOIR PLUS